Veru Announces Pricing of $25 Million Public Offering

Core Points - Veru Inc. announced a public offering of 1,400,000 shares of common stock, pre-funded warrants for 7,000,000 shares, and Series A and B warrants for 8,400,000 shares each, with a combined offering price of $3.00 per share [1][2] - The gross proceeds from the offering are expected to be approximately $25.2 million, with potential additional proceeds of about $50.4 million if all warrants are exercised [2] - The net proceeds will primarily fund the development of enobosarm, particularly for the Phase 2b PLATEAU clinical study, and will also cover working capital and general corporate purposes [3] Offering Details - The offering includes common stock, pre-funded warrants, and Series A and B warrants, all sold by Veru under a previously filed shelf registration statement [4] - The offering is expected to close on or about October 31, 2025, pending customary closing conditions [1] Company Overview - Veru Inc. is a late clinical stage biopharmaceutical company focused on innovative medicines for cardiometabolic and inflammatory diseases [6]